|
Modsite:
QSRPRSCtWPLQRPE
SwissProt
Entrez-Gene
|
|
Orthologous residues
|
|
FOXO3A (human): T32‑p, FOXO3A (mouse): T32‑p, FOXO3A (rat): T32‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'neuron, cerebellar granule'-brain, 293T (epithelial), CCL39 (fibroblast)
|
|
Cellular systems studied:
cell lines, primary cultured cells
|
|
Species studied:
hamster, human, rat
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
| Type |
Enzyme |
Evidence |
Notes |
|
KINASE
|
Akt1 (human)
|
genetic transfer of constitutively active upstream enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
| Treatments, proteins and their effect on site modification: |
| Treatments |
Referenced Treatments |
Manipulated Protein |
Referenced Protein |
Effect |
Notes |
|
IGF-1
|
|
|
|
increase
|
|
|
LY294002
|
IGF-1
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization, molecular association, regulation
|
|
Modification regulates interactions with:
|
| Interacting molecule |
Interacting domains |
Effect |
Consequences (function) |
Consequences (process) |
Detection assays |
|
14-3-3 zeta (mouse)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|